Budesonide / formoterol

Known as: BUDESONIDE/FORMOTEROL, formoterol and budesonide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2016
02420022016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is associated with rapid decline in lung… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2013
2013
BACKGROUND Beta-agonist overuse is associated with adverse outcomes in asthma, however, the relationships between different… (More)
Is this relevant?
2008
2008
Budesonide/formoterol is a combination of an inhaled corticosteroid plus a long-acting beta(2)-agonist available as a dry-powder… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2007
2007
BACKGROUND Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
BACKGROUND Budesonide/formoterol (Symbicort) Maintenance and Reliever Therapy (SMART) is an effective asthma-management approach… (More)
Is this relevant?
2006
2006
UNLABELLED We aimed to compare the efficacy and safety of budesonide/formoterol (Symbicort) with budesonide alone (Pulmicort) or… (More)
Is this relevant?
2004
2004
BACKGROUND Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable… (More)
Is this relevant?
2003
2003
This open, multinational, randomised, parallel-group, six-month extension conducted in the Swedish centres of a previous six… (More)
Is this relevant?
2002
2002
The aim of this study was to evaluate the efficacy (expressed as effect on lung function) and tolerability of Symbicort… (More)
Is this relevant?
2002
2002
The aim of this study was to compare the safety and efficacy of budesonide/formoterol 160/4.5 microg, two inhalations twice daily… (More)
Is this relevant?